TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02987205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra
Description: NLF correction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: NLF Correction
Study: NCT02335164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax1
Description: Delta inulin adjuvant formulation 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax2
Description: Delta inulin adjuvant formulation 2
Study: NCT02145429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving therapy and Brief Behavioral Treatment of Insomnia
Description: Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services.
Study: NCT04998175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventriculo-peritoneal shunt
Description: A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
Study: NCT01143116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver-nitrate coated catheter (Catheter A)
Description: Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Degradable silver particle-coated catheter (Catheter B)
Description: Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
Study: NCT00850629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal lifestyle intervention
Description: After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no intervention, only follow up
Study: NCT01070186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg/day for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Conducted prior to administration of sunitinib therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Nephrectomy 2-4 weeks after last dose of Sunitinib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarkers
Description: Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib
Study: NCT02883010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Softport V1.6
Description: PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Care path normally used by the hospital
Study: NCT04057313

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee
Description: Coffee used will be the boiled unfiltered Arabica coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coffee
Description: Coffee used will be the boiled unfiltered Arabica coffee
Study: NCT00125138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone HCl
Description: 20 mg/day. Strength of melperone syrup is 5 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone HCl
Description: 40 mg/day. Strength of melperone syrup is 5 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone HCl
Description: 60 mg/day. Strength of melperone syrup is 5 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Syrup formulation
Study: NCT02776904

Intervention type: OTHER
Group type: OTHER
Intervention: Immediate Post-concussion Assessment and Cognitive Testing
Description: Computerized assessment that provides information related to visual reaction time and visual memory.

Intervention type: OTHER
Group type: OTHER
Intervention: Gait with single and dual task
Description: Walking alone and then walking while performing a memory task on a tablet.

Intervention type: OTHER
Group type: OTHER
Intervention: Gait with single and dual task
Description: Walking alone and then walking while performing a memory task on a tablet.

Intervention type: OTHER
Group type: OTHER
Intervention: Y-Balance test
Description: Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
Study: NCT02335164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax2
Description: Delta inulin adjuvant formulation 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax2
Description: Delta inulin adjuvant formulation 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax2
Description: Delta inulin adjuvant formulation 2
Study: NCT03929718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: receive spironolactone treatment after CTI ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Spironolactone
Description: no spironolactone treatment
Study: NCT02975219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: 4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
Study: NCT00773474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
Study: NCT02897518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imago V-Balde
Description: the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
Study: NCT03945474

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: See description in sham arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation, OMT
Description: See description in OMT arm
Study: NCT01679379

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable suture group
Description: Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non absorbable suture group
Description: Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
Study: NCT04142021

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography
Description: Surgery planning done based solely on coronary computed tomography angiography.
Study: NCT04164615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB221
Description: GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.
Study: NCT02877823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Healthy Lifestyle Education, bottled water, pedometer, family navigator service

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Healthy Lifestyle Education
Study: NCT01730209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus once daily titrated to trough levels of 5-10 ng/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04760366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial- muscular lengthening therapy
Description: Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching's of iliopsoas muscle
Description: Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the conventional therapy
Description: the conventional therapy

Intervention type: OTHER
Group type: OTHER
Intervention: the conventional therapy
Description: the conventional therapy
Study: NCT04455321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture materials effect on istmocel
Description: Effect of suture materials with different absorption times on istmocel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture materials effect on istmocel
Description: Effect of suture materials with different absorption times on istmocel
Study: NCT02776033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Study: NCT02776904

Intervention type: OTHER
Group type: OTHER
Intervention: Y-Balance test
Description: Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.

Intervention type: OTHER
Group type: OTHER
Intervention: Psychomotor Vigilance Task
Description: Assessment measuring reaction time based on auditory cues.
Study: NCT01590524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Progressive Muscle Relaxation
Description: Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
Study: NCT03385395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OctaAlpha1
Description: For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glassia
Description: For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
Study: NCT00807456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
Study: NCT01070654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 40/30 recruitment manoeuvre
Description: The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: continuous positive airway pressure (CPAP)
Study: NCT03480529

Intervention type: DRUG
Intervention: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
Description: Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
Study: NCT01710215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT Screening Strategy
Description: * Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colon Screening Strategy
Description: * Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up.
Study: NCT03084042

Intervention type: DEVICE
Intervention: fMRI
Study: NCT05425537

Intervention type: OTHER
Intervention: Drowning incident
Description: Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid

Intervention type: OTHER
Intervention: Drowning incident
Description: Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid
Study: NCT02790749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjunctive hip arthroscopy to accompany PAO
Description: This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAO without adjunctive hip arthroscopy
Description: This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
Study: NCT04120025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragm Training
Description: training on isolated abdominal breathing with proper effort and hold time to promote strengthening
Study: NCT00411606

Intervention type: PROCEDURE
Intervention: Thermography
Description: Subjects will have a picture of their face taken with a thermal camera
Study: NCT00229242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic-Based or Non-Diuretic Based Hypertension Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic-Based or Non-Diuretic Based Hypertension Therapy
Study: NCT03098576

Intervention type: OTHER
Intervention: Matched targeted drug treatment
Description: Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.

Intervention type: OTHER
Intervention: Unmatched standard of care
Description: All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group.
Study: NCT01985035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Reduction of energy intake in order to weight loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Reduction of energy intake in order to weight loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Reduction of energy intake in order to weight loss
Study: NCT03484650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Lidocaine bolus to be given 1 hour pre-operatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
Study: NCT03461601

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HCG Uterine flushing
Description: HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Intrauterine insemination (IUI)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IUI
Description: Intrauterine insemination (IUI)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal flushing with 10 ml normal saline
Description: Flushing of the vagina with 10 ml of saline
Study: NCT03382587

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day
Study: NCT02945969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet
Description: Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
Study: NCT00626457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss/lifestyle interventions
Description: 6-month intervention (28 weekly classes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight-loss/lifestyle interventions
Description: 6-month intervention (28 weekly classes)
Study: NCT01579747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nerve stimulation
Description: Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
Study: NCT02237092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of IAP
Description: The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
Study: NCT04679493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC7 100 mg single
Description: The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC7 200 mg single
Description: The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
Study: NCT03084042

Intervention type: DEVICE
Intervention: fMRI

Intervention type: DEVICE
Intervention: fMRI
Study: NCT03939078

Intervention type: RADIATION
Intervention: CO2 fractional ablative laser
Description: 3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
Study: NCT01972685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryobiopsy biopsy
Description: Cryobiopsy vs. Transbronchial vs. VATS biopsy
Study: NCT04264637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (BAYR9258)
Description: Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (BAYR9258)
Description: Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
Study: NCT00514540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 120 mg/m\^2 daily for 3 days of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 for 3 days of 21 day cycle.